Nastech’s intellectual property estate includes rights to issued and pending patent applications relating to RNA-based therapeutics which have broad claims on their development, delivery and use in treating diseases.
Steven Quay, chairman, president and CEO of Nastech, said: “The transfer of intellectual property rights for RNA-based therapeutics from Nastech to MDRNA is an important step in the process of creating MDRNA as an independent company. We believe MDRNA independence will ultimately enhance Nastech shareholder value. The MDRNA intellectual property estate includes rights to patents and patent applications covering technologies for the development and delivery of RNA-based therapeutics as well as their use in treating diseases. We believe that this agreement provides a strong foundation for MDRNA and will be important in attracting external funding for MDRNA.”